MX2019003544A - Composiciones que comprenden un ligando de union al receptor cannabinoide. - Google Patents

Composiciones que comprenden un ligando de union al receptor cannabinoide.

Info

Publication number
MX2019003544A
MX2019003544A MX2019003544A MX2019003544A MX2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A
Authority
MX
Mexico
Prior art keywords
receptor binding
binding ligand
cannabinoid receptor
compositions
medicament
Prior art date
Application number
MX2019003544A
Other languages
English (en)
Inventor
Günther Bernhard
Löscher Frank
Krösser Sonja
Steven Philipp
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2019003544A publication Critical patent/MX2019003544A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Abstract

La presente invención proporciona una composición farmacéutica que comprende: a) una cantidad terapéuticamente eficaz de al menos un ligando de unión al receptor cannabinoide, y b) un vehículo líquido que comprende al menos un alcano semifluorado; así como el uso de dichas composiciones farmacéuticas como un medicamento.
MX2019003544A 2016-09-28 2017-09-27 Composiciones que comprenden un ligando de union al receptor cannabinoide. MX2019003544A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16191194 2016-09-28
EP17168172 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (1)

Publication Number Publication Date
MX2019003544A true MX2019003544A (es) 2019-09-19

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003544A MX2019003544A (es) 2016-09-28 2017-09-27 Composiciones que comprenden un ligando de union al receptor cannabinoide.

Country Status (10)

Country Link
US (1) US20190343793A1 (es)
EP (2) EP3698785A1 (es)
JP (1) JP2019534867A (es)
KR (1) KR20190060787A (es)
CN (1) CN109803650A (es)
AU (1) AU2017333420A1 (es)
BR (1) BR112019006194A2 (es)
CA (1) CA3036313A1 (es)
MX (1) MX2019003544A (es)
WO (1) WO2018060282A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2788060C (en) 2010-03-17 2017-07-11 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP3181119B1 (en) 2012-09-12 2019-07-10 Novaliq GmbH Semifluorinated alkane compositions for use in the treatment of keratoconjunctivitis sicca
ES2803248T3 (es) 2015-09-30 2021-01-25 Novaliq Gmbh 2-perfluorohexil octano para administración oftálmica
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
MX2019003363A (es) 2016-09-22 2019-10-02 Novaliq Gmbh Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
EP3515467B1 (en) 2016-09-23 2023-11-29 Novaliq GmbH Ophthalmic compositions comprising ciclosporin
US10732712B2 (en) * 2016-12-27 2020-08-04 Facebook Technologies, Llc Large scale integration of haptic devices
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
JP2020536614A (ja) 2017-10-04 2020-12-17 ニューマ・リスパイラトリー・インコーポレイテッド 呼吸により電気的に作動するインライン液滴送達装置および使用方法
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
JP2021502178A (ja) 2017-11-08 2021-01-28 ニューマ・リスパイラトリー・インコーポレイテッド 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法
MX2020009132A (es) 2018-03-02 2020-12-11 Novaliq Gmbh Composiciones farmaceuticas que comprenden nebivolol.
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
KR102534570B1 (ko) * 2019-02-01 2023-05-18 에어리 파마슈티컬즈, 인코포레이티드 근시의 치료를 위한 화합물, 조성물 및 방법
AU2021358490A1 (en) * 2020-10-05 2023-06-01 Max Biology Co. Ltd. Cannabinoid-containing compositions and use for treating and preventing diseases
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
WO2022271848A1 (en) 2021-06-22 2022-12-29 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
CA3234880A1 (en) * 2021-10-13 2023-04-20 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
AU2007281918A1 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
PL2352497T3 (pl) 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
JP6352266B2 (ja) * 2012-09-12 2018-07-04 ノバリック ゲーエムベーハー 半フッ化アルカンの混合物を含む組成物
EP3181119B1 (en) * 2012-09-12 2019-07-10 Novaliq GmbH Semifluorinated alkane compositions for use in the treatment of keratoconjunctivitis sicca
CN106061490A (zh) 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 一种治疗和预防眼部疾病症状或体征的方法及组合物
ES2784229T3 (es) 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Also Published As

Publication number Publication date
CA3036313A1 (en) 2018-04-05
JP2019534867A (ja) 2019-12-05
KR20190060787A (ko) 2019-06-03
EP3518921A1 (en) 2019-08-07
BR112019006194A2 (pt) 2019-06-18
EP3698785A1 (en) 2020-08-26
EP3518921B1 (en) 2021-08-11
WO2018060282A1 (en) 2018-04-05
AU2017333420A1 (en) 2019-04-04
CN109803650A (zh) 2019-05-24
US20190343793A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
MX2019003544A (es) Composiciones que comprenden un ligando de union al receptor cannabinoide.
MX2022010168A (es) Moduladores de calpainas y usos terapeuticos de los mismos.
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX2018005340A (es) Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos.
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
MY195244A (en) Muscarinic Agonists
MX2016014515A (es) Composicion topica de crema gel.
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
EP3957723A3 (en) Engineered ligase variants
PH12019502692A1 (en) Anti-cancer combination therapy
MX2019001121A (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion.
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
PH12015502523A1 (en) Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
WO2018127612A3 (en) Compositions comprising lespedeza plant extract
MX2018015125A (es) Nuevos compuestos antibacterianos.
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
IL276888A (en) Pharmaceutical compositions containing timolol
AU2018279184A1 (en) Anti-TrkB antibodies
MX2019007574A (es) Metodos de tratamiento de sindrome de intestino irritable con formulaciones modificadas o de liberacion retardada de linaclotida.
EP3875091A4 (en) Pharmaceutical composition containing antitumor agent